Shrinidhi Nathany
Overview
Explore the profile of Shrinidhi Nathany including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Batra U, Singh A, Nathany S, Dewan A, Sharma M, Amrith B, et al.
Discov Oncol
. 2025 Mar;
16(1):286.
PMID: 40056282
Background: Patients with Non-small Cell Lung Cancer (NSCLC) presenting with Mesenchymal-epithelial transition exon 14 skipping mutation (MET ex14) have an unfavorable prognosis with traditional therapies. MET inhibitors have altered the...
2.
Batra U, Sharma M, Jain P, Narayan S, Jain A, Soni S, et al.
Indian J Cancer
. 2025 Feb;
61(4):671-675.
PMID: 39960693
Introduction: Afatinib, a second-generation EGFR TKI, was approved in 2015 for the treatment of metastatic NSCLC in India. We aimed to evaluate the clinical outcomes of Afatinib therapy in a...
3.
Batra U, Nathany S
Oncol Rev
. 2025 Jan;
18():1445826.
PMID: 39834530
Non-small-cell lung cancer (NSCLC) is the poster child of personalized medicine. With increased knowledge about biomarkers and the consequent improvement in survival rates, NSCLC has changed from being a therapeutic...
4.
Noronha V, Budukh A, Chaturvedi P, Anne S, Punjabi A, Bhaskar M, et al.
Lancet Reg Health Southeast Asia
. 2024 Aug;
27:100430.
PMID: 39157507
Lung cancer varies between Caucasians and Asians. There have been differences recorded in the epidemiology, genomics, standard therapies and outcomes, with variations according to the geography and ethnicity which affect...
5.
Mehta A, Diwan H, Nathany S, Batra U, Gupta M, Panigrahi M, et al.
Clin Pathol
. 2024 Aug;
17:2632010X241269373.
PMID: 39139859
Advanced Non-Small Cell Lung Carcinoma (NSCLC) patients with gene rearrangement have shown significant therapeutic responses to tyrosine kinase inhibitors approved by the US Food and Drug Administration, with approximately 40...
6.
Batra U, Nathany S, Nath S, Jose J, Sharma T, P P, et al.
Lancet Reg Health Southeast Asia
. 2024 May;
24:100352.
PMID: 38756151
Background: The prognosis of lung carcinoma has changed since the discovery of molecular targets and their specific drugs. Somatic Epidermal Growth Factor Receptor () mutations have been reported in lung...
7.
Batra U, Nathany S, Sharma M, Saha S, Kumar D, Jose J, et al.
South Asian J Cancer
. 2024 May;
13(1):57-62.
PMID: 38721103
Ullas BatraIt is well known that patients with cancer are at an increased risk of severe COVID-19. There are no reports that depict the differences in outcomes in cancer patients...
8.
Kapoor R, Mehta A, Sharma A, Nathany S, Diwan H, Bansal D
Diagn Pathol
. 2024 Mar;
19(1):54.
PMID: 38509523
Melanocytic lesions involving the central nervous system are extremely rare and pose a diagnostic challenge owing melanoma being the third most common malignancy metastasizing to the spine. Morphology and immunohistochemistry...
9.
Batra U, Nathany S, Sharma M, Jain P, Mehta A, Bansal A
J Cancer Res Ther
. 2024 Feb;
19(7):2045-2047.
PMID: 38376315
In-frame fusions in NTRK genes, with intact kinase domain, have been reported to occur at higher frequencies in rare tumors like infantile fibrosarcoma, congenital mesoblastic nephroma, and secretory carcinoma, whereas...
10.
Pasricha S, Jajodia A, Sharma A, Bansal D, Batra U, Gupta G, et al.
J Cancer Res Ther
. 2023 Jul;
19(3):816-818.
PMID: 37470617
Nuclear protein in testis (NUT) midline carcinoma is a poorly differentiated tumor, is more common in midline anatomic sites, and involves young adults and children mainly. Primary pulmonary NUT midline...